估算婴儿/幼儿接种MenACWY疫苗可预防的潜在病例数
研究利用英国两项研究数据重新校准年龄别携带率曲线,用动态传播模型评估青少年MenACWY接种联合婴儿3或12月龄接种的间接与直接效果。结果显示青少年接种可有效控制ACWY群携带与疾病,婴儿/幼儿MenACWY接种减少病例的作用有限,3月龄接种比12月龄接种可预防更多病例。
要点
- 青少年MenACWY接种可有效控制A、C、W、Y群携带与疾病。
- 婴儿/幼儿MenACWY接种对减少病例的作用有限。
- 3月龄接种比12月龄接种可预防更多病例。
核心结论
- 若青少年MenACWY疫苗接种率保持高位且婴儿4CMenB程序维持,作者建议婴儿/幼儿MenACWY剂次可预防的病例很少。
研究设计与样本
- 利用英国两项研究数据重新校准年龄别携带率曲线,估算ACWY与非ACWY菌株所致携带比例。
- 采用动态传播模型评估青少年MenACWY接种的间接效应与3或12月龄MenACWY接种的直接效应,并模拟COVID-19封锁期传播。
主要发现
- 预测青少年接种可有效控制A、C、W、Y群携带与疾病。
- 假设大流行情景下青少年疫苗高接种率持续,预测2025年MenACWY携带率低于1%。
- 所有情景中婴儿/幼儿MenACWY程序对病例减少的影响均有限。
- 3月龄接种MenACWY比12月龄接种可预防更多病例。
- 青少年接种持续情况下,2025年出生队列中3月龄MenACWY剂次预计可避免3至22例病例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Meningococcal disease control in the UK relies on various vaccines, with the discontinuation of the Hib/MenC combination vaccine Menitorix® in 2018 necessitating reassessment of the immunisation strategy. The quadrivalent MenACWY vaccine emerges as a promising long-term solution, already integrated into the teenage immunisation regimen. While indirect control of group W and C cases is anticipated through existing programs, the high incidence of meningococcal disease in infancy underscores the potential benefits of infant/toddler vaccination. METHODS: Utilizing data from two UK studies, we recalibrated age-specific carriage prevalence curves and estimated the proportion of meningococcal carriage attributed to ACWY and non-ACWY strains. Employing a dynamic transmission model, we evaluated the combined indirect effects of the teenage MenACWY vaccination initiative and the direct impact of administering MenACWY vaccine at either 3 or 12 months, alongside ongoing 4CMenB vaccination efforts. Given the pandemic-induced decline in cases and alterations in social contact patterns reported in prior research, we also simulated the transmission model to reflect periods of COVID-19 lockdown. RESULTS: Our projections indicate effective control of carriage and disease associated with groups A, C, W, and Y through the teenage vaccination campaign. Assuming sustained high uptake of teenage vaccines amid pandemic scenario, we forecast MenACWY carriage prevalence to be below 1% by 2025. Across all scenarios, the impact of an infant/toddler MenACWY program on case reduction remains modest. Notably, administering the MenACWY dose at 3 months yields a greater number of prevented cases compared to administration at 12 months. With sustained uptake of teenage vaccination, our estimates suggest that between 3 and 22 cases could be averted in a 2025 birth cohort through a 3-month MenACWY dose. CONCLUSIONS: Provided teenage uptake remains high and the infant 4CMenB programme is maintained, we suggest that few cases will be prevented from an infant/ toddler MenACWY dose.
引用
- Adams L, Prasinou AK, Hadley L, et al. Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine. Vaccine. 2024. PMID: 39178766. doi:10.1016/j.vaccine.2024.126240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。